Find clinical trials for Leukemia in Houston, TX
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near Houston, TX, USA:
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Houston, Texas, United States and 51 other locations
is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia...
Phase 1
Houston, Texas, United States
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Houston, Texas, United States and 173 other locations
This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia...
Phase 1, Phase 2
Houston, Texas, United States
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Houston, Texas, United States and 56 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Houston, Texas, United States and 10 other locations
NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, includi...
Phase 1
Houston, Texas, United States and 3 other locations
single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...
Phase 1
Houston, Texas, United States and 13 other locations
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)...
Phase 1, Phase 2
Houston, Texas, United States and 7 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Houston, Texas, United States and 22 other locations
Clinical trials
Research sites
Resources
Legal